Navigation Links
A novel vaccine proves a shot in the arm for colorectal cancer patients

British researchers have produced a vaccine that activates the immune systems in colorectal cancer patients to attack cancerous cells. //

During a clinical trial of 67 patients, researchers at the University of Nottingham discovered that when the vaccines were injected pre and post surgery of the cancerous growth, it activated the immune cell production in nearly 70 percent of patients. The November 15 issue of Clinical Cancer Research has carried the details of this research.

"This is the first vaccine shown to stimulate TNF-alpha – an immune-system protein that is very effective at killing cancer cells," said Lindy Durrant, senior author of the study and professor of cancer immunotherapy at the university.

The vaccine works by stimulating the patients' immune response to generate infection-fighting white blood cells called T cells, which in turn produce immune system proteins called cytokines that destroy cancer cells. The antibody contained in the vaccine, called 105AD7, was cloned from a patient who survived seven years with liver metastases from colorectal cancer, Durrant explained.

"This is very unusual as most patients die within one year of getting liver metastases," she said. "I thought if this antibody had helped this patient, if we could clone it, it might help others."

105AD7 is structurally similar to CD55, a protein that attaches to sugar molecules and is overexpressed in colorectal cancer cells, protecting them from attack by the body's immune system. While low levels of CD55 occur in all cells exposed to the immune system, increased expression of the protein has been observed in multiple types of tumors, including up to 80 percent of colorectal cancers.

During the trial -- the largest to date looking at 105AD7 plus surgery -- 67 patients with colorectal cancer who were scheduled for surgery to remove their primary tumor were randomly assigned to receive either 100 micrograms of 105AD 7 with a powder to help absorb the vaccine, 105AD7 along with BCG (a bacteria used to stimulate the immune system in cancer patients) during the first immunization and the powder in subsequent vaccinations, or no treatment.

The patients, who had varying degrees of disease, averaged age 66. Twenty-eight patients had colon cancer while in 39 patients the primary tumor was located in the rectum.

Patients were immunized before surgery on the day they were recruited for the study, and again two weeks later if surgery had not yet been performed. The vaccines were continued three, six and 12 weeks after surgery, and then at three monthly intervals up to a maximum of 24 months after surgery. Blood samples were collected from the patients during recruitment, at surgery, and at the time of the three-, six- and 12-week post-operative immunizations. Additional blood samples were acquired one month after each subsequent immunization.

Laboratory tests of the blood samples indicated that a T-cell response against the vaccine was recorded in the majority of patients. The responses tended to have two peaks: one following the start of the immunization schedule and another several months later, after additional immunizations. About 70 percent of patients produced both TNF-alpha and GM-CSF – a protein that stimulates white blood cell production – in response to both the vaccine and to CD55.

"The immune responses to both the vaccine and CD55 were measurable, adding support to the use of CD55 as a target in cancer treatment," Durrant said.

Nineteen of the patients died during the follow-up period. Durrant and colleagues noted that the trial was not designed to study the effect of the vaccines on survival.



Source-Eurekalert
SV
'"/>




Related medicine news :

1. A novel augmentation
2. Gene enchances radiation therapy - A novel approach to fight cancer
3. Cessation of blood supply to cancer cells may curtail spread, novel research
4. Lice now dried to death by novel dryer
5. New hope for cancer victims – will vaccine cure the deadly bug
6. New vaccine helps allergy and asthma patients
7. Man against HIV – new vaccine ready for human trials
8. New vaccine helps allergy and asthma patients
9. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
10. HIV did not arise from polio vaccine
11. Double impact vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... , ... February 12, 2016 , ... With the exception of restorative dentistry, to date ... decay. With the recent approval by the FDA, there is a now a new ... fluoride varnish, SDF is very simple and quick to apply. The application is as ...
(Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers outdoor training classes which ... to get fit and healthy. Located in Phoenixville, PA, the classes are structured as ... for horseback riders who want to lose weight and tone up. This class offers ...
(Date:2/11/2016)... ... February 11, 2016 , ... According to an article ... as a weight loss dietary supplement, is being recalled due to the discovery that ... because there is not a single supplement on the market proven to help people ...
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors from Western University ... Match Program Tuesday, February 9, taking one of the final steps in their ... education positions across the country. Of the 103 student-doctors who comprise the College ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent ... cosmetic procedures. Along with performing procedures, the magazine also highlights that Dr. Sadati ... procedures. One of the most common procedures he performs is his natural facelift. ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. ... will create 1,400 jobs throughout Western New ... partnership with the SUNY Polytechnic Institute, includes a major ... Building in Buffalo , as well ... manufacturing facility in Dunkirk . The ...
(Date:2/11/2016)... , Feb. 11, 2016 AAIPharma ... provider of custom manufacturing and development services for ... sterile fill-finish capabilities and capacity in its ... in demand has driven several recent investments. ... it had one filling line with small-scale lyophilization. ...
Breaking Medicine Technology: